Home›Stock Screener›Brooks Laboratories›Financial Statements

Brooks Laboratories Complete Financial Statements

7 Years of Data
2026 - 2020

In FY2026, Brooks Laboratories (BROOKS) reported revenue ₹22 Cr, net profit ₹2 Cr and EPS ₹0.52, with a net profit margin of 9.1% and ROE of 1.6%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse BROOKS institutional holdings to track promoter, FII and institutional holdings.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 9.09% 2026 data
EBITDA Margin 9.09% 2026 data
Operating Margin 3.00% 2026 data
Return on Assets 1.35% 2026 data
Return on Equity 1.63% 2026 data

Balance Sheet Ratios

Current Ratio 9.25 2026 data
Equity Ratio 83.11% 2026 data
Asset Turnover 0.15 2026 data

BROOKS Revenue, Net Profit & EBITDA — Year-on-Year Growth

BROOKS YoY (Mar 2025 vs Mar 2026) — revenue -8.3%, net profit +200.0%, EBITDA +300.0%, expenses -20.0%. For live price, earnings ratios and company overview, see BROOKS share price.

Revenue Growth
-8.3%
Year-over-Year
Net Profit Growth
+200.0%
Year-over-Year
EBITDA Growth
+300.0%
Year-over-Year
Expense Growth
-20.0%
Year-over-Year
Assets Growth
+19.4%
Year-over-Year
Equity Growth
+25.5%
Year-over-Year
Operating Cash Flow Growth
+130.0%
Year-over-Year
Financing Cash Flow Growth
+320.0%
Year-over-Year

BROOKS Income Statement — Revenue, EBITDA & Net Profit

Brooks Laboratories revenue ₹22 Cr, EBITDA ₹2 Cr, net profit ₹2 Cr, EPS ₹0.52 (2026) — net profit margin 9.1%. Examine BROOKS earnings report for recent quarterly revenue, profit and EPS trends.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022 Sept 2021 Mar 2021 Jun 2021 Dec 2021 Sept 2020 Jun 2020 Dec 2020
Revenue 22 30 24 33 22 21 18 18 21 24 13 16 22 19 29 17 16 22 15 23 19 30 13 22
Expenses 20 21 25 22 16 24 27 20 22 25 16 20 25 27 32 26 24 26 19 22 25 24 13 22
EBITDA 2 9 -1 10 6 -3 -9 -2 -2 -1 -4 -4 -3 -9 -4 -9 -8 -4 -4 1 -6 6 0 0
Operating Profit Margin % 3.00% 11.00% -5.00% 12.00% 4.00% -16.00% -54.00% -11.00% -7.00% -5.00% -29.00% -25.00% -15.00% -51.00% -14.00% -50.00% -56.00% -20.00% -31.00% -2.00% -34.00% 18.00% -2.00% -3.00%
Depreciation 0 0 0 0 0 0 1 0 0 0 0 0 0 2 2 2 2 2 2 2 2 2 2 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1
Profit Before Tax 2 8 -1 10 6 -4 -10 -2 -2 -2 -4 -5 -4 -12 -7 -11 -11 -7 -7 -2 -9 3 -3 -3
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0 -4 -1 -2 -2 -2 10 -1 -1 0 0 0
Net Profit 2 8 -2 10 6 -4 -10 -2 -2 -2 -4 -5 -4 -8 -6 -9 -10 -5 -17 -1 -7 3 -3 -3
Earnings Per Share (₹) 0.52 2.71 -0.54 3.25 1.87 -1.51 -3.77 -0.94 -0.82 -0.60 -1.75 -1.81 -1.51 -3.19 -1.46 -3.80 -2.03 -1.97 -6.93 -0.47 -3.14 1.35 0.00 -1.03

BROOKS Balance Sheet — Assets, Liabilities & Shareholders' Equity

BROOKS total assets ₹148 Cr, total equity ₹123 Cr, total liabilities ₹ Cr (2026) — ROE 1.6%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021
ASSETS
Total Assets 148 124 90 110 196 162
Current Assets 37 34 31 28 61 47
Fixed Assets 16 14 14 15 110 108
Capital Work in Progress 1 0 0 0 15 1
Investments 11 74 43 64 0 0
Other Assets 0 36 34 31 71 54
LIABILITIES
Total Liabilities
Current Liabilities 4 3 2 3 13 19
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 123 98 66 74 134 79
Share Capital 30 30 26 25 25 25
Reserves & Surplus 93 69 39 49 63 54

BROOKS Cash Flow Statement — Operating, Investing & Financing

Brooks Laboratories operating cash flow ₹3 Cr, investing ₹-45 Cr, financing ₹42 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021
Operating Activities 3 -10 -15 -37 5
Investing Activities -45 0 1 -25 -5
Financing Activities 42 10 11 64 1
Net Cash Flow 0 0 -3 2 1